273 related articles for article (PubMed ID: 22027691)
1. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
[TBL] [Abstract][Full Text] [Related]
5. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
6. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
7. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
[TBL] [Abstract][Full Text] [Related]
8. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
9. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
[TBL] [Abstract][Full Text] [Related]
10. Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.
Luo D; Fraga-Lauhirat M; Millings J; Ho C; Villarreal EM; Fletchinger TC; Bonfiglio JV; Mata L; Nemesure MD; Bartels LE; Wang R; Rigas B; Mackenzie GG
Carcinogenesis; 2019 Dec; 40(12):1480-1491. PubMed ID: 30994173
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
12. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.
Lee JH; Park KS; Alberobello AT; Kallakury B; Weng MT; Wang Y; Giaccone G
Clin Cancer Res; 2013 Dec; 19(24):6777-86. PubMed ID: 24158701
[TBL] [Abstract][Full Text] [Related]
13. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
14. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
16. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
Mukthavaram R; Ouyang X; Saklecha R; Jiang P; Nomura N; Pingle SC; Guo F; Makale M; Kesari S
J Transl Med; 2015 Aug; 13():269. PubMed ID: 26283544
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
18. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.
Murakami T; Takigawa N; Ninomiya T; Ochi N; Yasugi M; Honda Y; Kubo T; Ichihara E; Hotta K; Tanimoto M; Kiura K
Lung Cancer; 2014 Jan; 83(1):30-6. PubMed ID: 24238495
[TBL] [Abstract][Full Text] [Related]
19. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
de Groot J; Liang J; Kong LY; Wei J; Piao Y; Fuller G; Qiao W; Heimberger AB
Oncotarget; 2012 Sep; 3(9):1036-48. PubMed ID: 23013619
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
Sai K; Wang S; Balasubramaniyan V; Conrad C; Lang FF; Aldape K; Szymanski S; Fokt I; Dasgupta A; Madden T; Guan S; Chen Z; Alfred Yung WK; Priebe W; Colman H
J Neurooncol; 2012 May; 107(3):487-501. PubMed ID: 22249692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
